A phase Ib/II, open-label, multi-center study of INC280 in combination with PDR001 or PDR001 single agent in advanced hepatocellular carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 12 Aug 2017
At a glance
- Drugs Capmatinib (Primary) ; PDR 001 (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 17 Mar 2017 Planned End Date changed from 3 Apr 2019 to 24 Dec 2018.
- 28 Feb 2017 Planned primary completion date changed from 1 Apr 2019 to 24 Dec 2018.